Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

Urine Test for Womb Cancer

Analysis based on 6 articles · First reported Sep 22, 2026 · Last updated Sep 23, 2026

Sentiment
5
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

This development could reduce healthcare costs associated with invasive diagnostic procedures and improve patient outcomes, potentially benefiting medical diagnostics companies and healthcare providers. However, the impact is likely limited to the UK healthcare sector in the near term, with broader market effects minimal until further validation and adoption.

Healthcare Medical Diagnostics

Researchers at University of Manchester and Manchester University NHS Foundation Trust have developed a simple, non-invasive test that analyzes cells collected from urine and vaginal fluid to help rule out womb cancer in women who experience bleeding after menopause. The study, published in The Lancet, involved 1,864 women attending seven hospitals in north-west England with postmenopausal bleeding. Of these, 99 were diagnosed with womb cancer. When urine and vaginal cell sample results were combined, the test correctly identified 80% of cancers and had a negative predictive value of 98.8% for womb cancer. It also detected 95.8% of high-grade tumours and 96.4% of cancers that had spread beyond the uterus, and picked up 100% of cancers in black women. Professor Adam Davidson of University of Manchester stated that the test could transform care for thousands of women each year by sparing them from invasive, uncomfortable, and costly procedures such as internal ultrasounds, biopsies, and hysteroscopies. The test is not accurate enough to rule out cancer on its own but could be used to triage women, fast-tracking high-risk cases for urgent investigation while reassuring lower-risk women. Researchers cautioned that the samples were assessed by highly trained specialist cytologists and further studies are needed to confirm the findings in routine practice. In the United Kingdom, around 10,200 women are diagnosed with womb cancer annually.

per
As lead researcher, she highlighted the potential of the test to transform care and reduce invasive testing.
Importance 70.0 Sentiment 10.0
cnt
The UK healthcare system could see reduced costs and improved care for women with postmenopausal bleeding.
Importance 50.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.